Pancreatic Cancer Research

ResearcherMayo ClinicNo recent work listed

Patrick Joseph Loehrer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1532-4660; OpenAlex author ID A5021904320. Sources: ClinicalTrials.gov.

Their work

Papers
7 (first author 0, last author 1)
Trials
3 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

1999: 1 trial · 2000: none · 2001: none · 2002: none · 2003: 1 trial · 2004: none · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 2 papers · 2012: none · 2013: none · 2014: 3 papers · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 trial · 2020: none · 2021: none · 2022: none · 2023: 1 paper

Papers 7

  1. Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198). Co-author DOI 10.1016/j.ejca.2023.02.030↗
  2. Adjuvant Gemcitabine and Gemcitabine-based Chemoradiotherapy Versus Gemcitabine Alone After Pancreatic Cancer Resection: The Indiana University Experience. Co-author DOI 10.1097/coc.0000000000000115↗
  3. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic ca… Co-author DOI 10.1016/j.ijrobp.2014.02.024↗
  4. Contribution of environment and genetics to pancreatic cancer susceptibility. Co-author DOI 10.1371/journal.pone.0090052↗
  5. Critical role of NF-κB in pancreatic cancer. Co-author DOI 10.18632/oncotarget.2624↗
  6. A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group stu… Last author DOI 10.1097/coc.0b013e3181e9c103↗
  7. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. Co-author DOI 10.1200/jco.2011.34.8904↗

Trials 3

  1. Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC) Principal investigator NCT04046887↗
  2. Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer Study chair NCT00057876↗
  3. Perillyl Alcohol Followed by Surgery in Treating Patients With Stage II or Stage III Pancreatic Cancer Study chair NCT00003769↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bert H. O’Neil · 1 shared paper, 2023 · strength 0.17
  2. Walid Labib Shaib · 1 shared paper, 2023 · strength 0.17
  3. Tanios Bekaii‐Saab · 1 shared paper, 2023 · strength 0.17
  4. Steven J. Cohen · 1 shared paper, 2023 · strength 0.17
  5. Bassel F. El‐Rayes · 1 shared paper, 2023 · strength 0.17
  6. Elena Gabriela Chiorean · 4 shared papers, 2011–2017 · strength 0.17
  7. Higinia Rosa Cardenes · 4 shared papers, 2011–2017 · strength 0.15
  8. John M. DeWitt · 2 shared papers, 2014 · strength 0.07
  9. Muhammad Rizwan Khawaja · 1 shared paper, 2017 · strength 0.07
  10. Lakshmi Prabhu · 1 shared paper, 2014 · strength 0.06
  11. Murray Korc · 1 shared paper, 2014 · strength 0.06
  12. Tao Lu · 1 shared paper, 2014 · strength 0.06
  13. Barbara A. Hocevar · 1 shared paper, 2014 · strength 0.04
  14. Lisa M. Kamendulis · 1 shared paper, 2014 · strength 0.04
  15. Romnee S. Clark · 1 shared paper, 2014 · strength 0.03
  16. Safi Shahda · 1 shared paper, 2014 · strength 0.03
  17. Kumaresan Sandrasegaran · 1 shared paper, 2014 · strength 0.03
  18. David F Cella · 1 shared paper, 2011 · strength 0.02
  19. Ramesh K. Ramanathan · 1 shared paper, 2011 · strength 0.02
  20. Steven R. Alberts · 1 shared paper, 2011 · strength 0.02
  21. Christopher H. Crane · 1 shared paper, 2011 · strength 0.02
  22. Al B. Benson · 1 shared paper, 2011 · strength 0.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.